SCHEMBL22014460

SCHEMBL22014460

C[C@H](O)CN1CCN(Cc2ccc(C(=O)NCCOP(=O)(O)O)cc2)CCN(C[C@H](C)O)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.55
HPGD P15428 1/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC1 Q13547 3/20 0.45
HDAC4 P56524 2/20 0.45
KCNH2 Q12809 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MCHR1 Q99705 4/20 0.44
CHRM1 P11229 2/20 0.44
HTR2A P28223 2/20 0.44
HDAC8 Q9BY41 1/20 0.44
LMNA P02545 3/20 0.44
CYP2D6 P10635 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22014464 0.83 HDAC6 (0.52) KMT2AHDAC6HDAC1HDAC4KCNH2
SCHEMBL24462542 0.82 HDAC6 (0.46) KMT2AHDAC6HDAC1HDAC4KCNH2
SCHEMBL22014467 0.79 HDAC1 (0.54) KMT2AHDAC6HDAC1HDAC4KCNH2
SCHEMBL10900938 0.76 CHKA (0.60) KMT2AHPGDHDAC6HDAC1HDAC4
SCHEMBL10903263 0.74 HDAC1 (0.52) KMT2AHDAC6HDAC1HDAC4KCNH2
SCHEMBL24672959 0.73 HDAC6 (0.43) HDAC6HDAC1HDAC4KCNH2KDM4E
SCHEMBL24673213 0.73 PGK1 (0.45) HDAC6HDAC1HDAC4KCNH2KDM4E
SCHEMBL22014462 0.72 HDAC1 (0.51) HDAC6HDAC1HDAC4KCNH2MCHR1
SCHEMBL22014470 0.71 HDAC1 (0.50) HDAC6HDAC1HDAC4KCNH2MCHR1
SCHEMBL24672693 0.71 HTT (0.41) KMT2AHDAC6HDAC1HDAC4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204065-A1 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-09-29 WO disclosed
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-31 US disclosed
WO-2020102820-A1 COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups SLC40A1, TAC3, ABCB7 KMT2A 3561/4885HPGD 2304/4885HDAC6 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.